Praxis Precision Medicines, Inc. (PRAX)
| Market Cap | 2.16B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.49M |
| Shares Out | 36.74M |
| EPS (ttm) | -1.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $56.51 |
| Previous Close | $56.45 |
| Change ($) | 0.06 |
| Change (%) | 0.10% |
| Day's Open | 56.87 |
| Day's Range | 55.36 - 58.30 |
| Day's Volume | 25,009 |
| 52-Week Range | 27.25 - 60.20 |
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the developmen...
- Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21 -
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such invest...
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the developmen...
CAMBRIDGE, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the developmen...
Nine IPOs and five SPACs went public this past week, and one IPO postponed.
CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the developmen...
Praxis Precision Medicines Inc. has increased the number of shares it plans to sell in its initial public offering by 35%, as the Massachusetts-based biopharmaceutical company developing treat...
Praxis Precision Medicines has filed proposed terms for its U.S. IPO.
Praxis Precision Medicines Inc. set terms for its initial public offering, in which the Massachusetts-based biopharmaceutical company developing treatments for central nervous system disorders...
About PRAX
Praxis Precision Medicines, a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremo... [Read more...]
| Industry Biotechnology | IPO Date Oct 16, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol PRAX |
Analyst Forecasts
According to 4 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price forecast is 65.33, which is an increase of 15.62% from the latest price.